Looking for some new additions to your portfolio after earnings season? Listed below are two ASX growth shares that have recently been given buy ratings by Goldman Sachs.
Hereâs why its analysts rate them highly right now:
Breville Group Ltd (ASX: BRG)
The first ASX growth share that is highly rated by Goldman Sachs following earnings season is Breville.
It is the leading appliance manufacturer behind brands such as Breville, Sage, Kambrook, and Baratza.
As many readers will be aware, these appliances are found in countless kitchens across Australia. And thanks to the companyâs ongoing and highly successful international expansion, you may have noticed them popping up in kitchens across Europe if you were holidaying abroad this winter.
Goldman Sachs is very positive on the company. It highlights that Breville is exposed to some powerful trends and its strong brands are well-placed to benefit from them.
Goldman has a buy rating and $24.70 price target on the companyâs shares.
ResMed Inc. (ASX: RMD)
Another ASX growth share that Goldman is tipping as a buy is ResMed.
It is a medical device company with a focus on sleep treatment and respiratory products that treat disorders including sleep apnoea and chronic obstructive pulmonary disease (COPD).
These are significant and growing markets to target. For example, the company highlights that upwards of 1 in 5 people are believed to suffer from sleep apnoea, with the vast majority currently undiagnosed. This bodes well for ResMedâs future growth, especially given its industry-leading products, high level of research and development, and wide distribution network.
Goldman Sachs currently has a buy rating and $36.80 price target on its shares.
The post Broker names 2 excellent ASX growth shares to buy right now appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now
See The 5 Stocks
*Returns as of August 4 2022
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- 3 top ASX growth shares analysts rate as buys
- Here are the top 10 ASX 200 shares today
- Analysts name 2 growing ASX shares as buys
- Breville share price lifts on record FY22 revenue and dividend boost
- 3 buy-rated ASX 200 shares that analysts love
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/Urn8ch9